EO Care, a leader in clinically guided cannabinoid-based healthcare treatment, announced today that Milliman, a premier global consulting and actuarial firm, has completed its review of EO Care’s proprietary cost impact model. This model is designed for employers and group plan sponsors to estimate potential healthcare cost impacts when using evidence-based, clinically guided cannabinoids to alleviate symptoms of cancer, chronic pain, sleep disorders/insomnia, and anxiety. (Click here to review report.)
Milliman’s report concluded that EO Care’s methodology for estimating the healthcare cost impact of its clinically guided cannabinoid-based care program is reasonable.
“Milliman’s review of our theoretical cost impact model methodology for cannabinoid-based treatment could not come at a better time for employers and group plan sponsors,” said Sean Collins, CEO of EO Care. “As momentum builds for the reclassification of cannabis to a less dangerous drug category, companies are looking to get ahead of the curve in responding to the expected rise in employee demand for reimbursement of their cannabinoid-based treatment for selected health issues. Research on cannabis efficacy is limited, but the EO Care cost impact model is a third-party validated model that can estimate potential healthcare impacts for employers and group plan sponsors.”
Collins noted that Milliman, known for its meticulous approach in methodology reviews, identified a few limitations in EO Care’s model related to the scarcity of actual healthcare claims-based research on cannabis use.
EO Care is poised to expand its clinically guided cannabinoid-based healthcare treatment services, offering education, 24/7 evidence-based healthcare guidance, a digital platform of medical cannabinoid products, and customized solutions with direct delivery to clients.
“The estimated healthcare cost savings of cannabinoid-based treatment identified by EO Care’s cost impact model are significant,” Collins continued. “Based on these estimates, integrating cannabinoid-based treatment into mainstream medicine can yield benefits for both members and employers/health plans.”
